Skip to main content
OpenTrials
Completed

NCT Number: NCT03104049

Pilot Study on the Effects of Neuromuscular Taping in Parkinson's Disease Patients

Parkinson's disease (PD) is a degenerative disorder characterized by a symptom triad consisting on: tremor, rigidity and bradykinesia . To these symptoms it is often added postural alteration that can stand in two different attitudes, such as the camptocormia and the syndrome of Pisa . Progressing in its evolution, PD becomes increasingly disabling, making it difficult or even impossible daily activities such as washing or dressing.The abnormal posture, with alteration of the limbs, the neck and trunk, is a recurring feature in PD, with a frequency of about 30%. Between 2% and 12.3% are more severe abnormalities such as camptocormia, the syndrome of Pisa and the anterocollis. Several studies disease plug in Neuromuscular Taping technique (NMT) among rehabilitative tools in degenerative neurological syndromes.

To the best of our knowledge, no applications were found in PD. Therefore, the current study was designed to evaluate quantitatively the effects of the NMT intervention on the trunk kinematics during standing position. More specifically, this study aims to compare the trunk kinematic variables of patients with PD who were treated with effective NMT versus those of the subjects who received only the pharmacological treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

60 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria
  • No other significant neurological or orthopedic problems
  • Age between 55 and 80 years
  • MDS-UPDRS item 3.13 Posture between mild and moderate (definite flexion, scoliosis or leaning to one side)
  • Patient able to walk independently or with minimal assistance for 10 meters
  • Medical treatment for Parkinson's Disease must be stable for at least two weeks prior to inclusion, and during the study. During the study, the dosage of anti-parkinsonian drug treatment should not change, if it is not deemed necessary by the investigator.

Exclusion criteria

  • Disability to understand instructions required by the study (Informed Consent Test of Comprehension)
  • primarily wheelchair bound
  • Skin abrasions
  • sensitive skin

Treatment and study plan

Neuromuscular taping

Device

NMT applications:

  • rhomboid major muscle
  • muscles abdominals
  • spinal muscles
  • pectoralis major muscles
  • gastrocnemius muscle
  • upper trapezius muscle
  • anterior muscles of the neck

Other names: NMT

Primary outcomes

  1. Change in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating scale total score between baseline evaluations and end of treatment

    Time frame: baseline and end of treatment (1 month)

    Clinical measures were summarized as means and standard deviations for all the 46 patients.

Secondary outcomes

  1. Change in the Parkinson Disease Quality of life 8 total score between baseline evaluations and end of treatment

    Time frame: baseline and end of treatment (1 month)

    Clinical measures were summarized as means and standard deviations for all the 46 patients.

  2. Change in the Non Motor Symptoms scale total score between baseline evaluations and end of treatment

    Time frame: baseline and end of treatment (1 month)

    Clinical measures were summarized as means and standard deviations for all the 46 patients.

  3. Change in the EuroQol 5 total score between baseline evaluations and end of treatment

    Time frame: baseline and end of treatment (1 month)

    Clinical measures were summarized as means and standard deviations for all the 46 patients.

  4. Change in the Freezing of Gait total score between baseline evaluations and end of treatment

    Time frame: baseline and end of treatment (1 month)

    Clinical measures were summarized as means and standard deviations for all the 46 patients.

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele Roma

Other

Collaborators

  • Politecnico di Milano

Registry information

Acronym: NMT-PD

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Apr 7, 2017
Registry last updated
Apr 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.